



Toxoplasmosis and Risk of Endothelial Dysfunction: Role of Oxidative Stress and Pro-Inflammatory Mediators

Hayder M. Al-Kuraishy^{1,*}, Azhar H. Al-Kuraishi², Salah Al-Windy³ and Ali I. Al-Gareeb¹

¹Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty College of Medicine, Al-Mustansiriya University, Baghdad, Iraq

²Microbiology Department, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq

³Department of Medical Microbiology, College of Science, Baghdad University, Baghdad, Iraq

*Corresponding author: Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty College of Medicine, Al-Mustansiriya University, P.O. Box: 14132, Baghdad, Iraq. Email: hayderm36@yahoo.com

Received 2019 June 21; Revised 2019 December 14; Accepted 2019 December 15.

Abstract

Background: Infection with *Toxoplasma gondii* (*T. gondii*) leads to activation of T-helper cells (Th-1 and Th-2) which are involved in the synthesis and release of different cytokines which may lead to endothelial dysfunction.

Objectives: To evaluate the endothelial function in patients with acute toxoplasmosis.

Methods: This case-control study involved 31 patients with toxoplasmosis aged 19 - 47 years matched with 20 healthy subjects. Anti-*T. gondii* antibody (IgG, IgM, IgA) was determined by direct antigen-antibody reaction. Interleukin-6 (IL-6), endothelin-1 (ET-1) and human malondialdehyde (MDA) serum levels were measured.

Results: IgM, IgG and IgA levels were high in the infected patients compared with controls ($P < 0.01$). Furthermore, IL-6 serum level was high in the infected patients compared with controls ($P < 0.01$). In addition, ET-1 level was high in acute toxoplasmosis (7.29 ± 4.59 pg/mL) compared with controls (3.11 ± 1.69 pg/mL) ($P < 0.01$). In addition, MDA serum level was high (9.34 ± 4.17 nmol/mL) compared with controls (2.87 ± 1.13 nmol/mL), ($P < 0.01$). In acute toxoplasmosis IgM serum level was significantly correlated with IgG ($r = 0.55$, $P = 0.001$), IgA ($r = 0.57$, $P = 0.0008$), IL-6 ($r = 0.45$, $P = 0.01$), ET-1 ($r = 0.51$, $P = 0.003$) and MDA ($r = 0.85$, $P = 0.0001$).

Conclusions: Acute toxoplasmosis is associated with significant oxidative stress and pro-inflammatory changes which contribute to development of endothelial dysfunction.

Keywords: Endothelial Dysfunction, *Toxoplasma gondii*, Endothelin-1

1. Background

Toxoplasmosis is a zoonotic disease with a wide range of clinical syndromes in humans caused by *Toxoplasma gondii* (*T. gondii*), a typical coccidian parasite which is an intracellular protozoan parasite (1). Humans can be infected by eating undercooked meat of infected animals, consuming food or water contaminated with cat feces, blood transfusion, organ transplantation, or transplacentally from mother to fetus which is the most serious one. Toxoplasmosis in early pregnancy is usually accompanied by severe damage to the fetus leading to abortion or congenital malformations (2).

The infective stage of *T. gondii* includes three stages, sporozoite, and tachyzoite which is the rapidly multiplying form, and bradyzoite which is tissue cystic form. The tachyzoite is involved in the clinical manifestations of acute toxoplasmosis, which is susceptible to the effect of host immunity and medications. Bradyzoite is less suscep-

tible and more resistance forms of the drugs and host immune system (3).

The prevalence of seropositivity for *T. gondii* fluctuates from 5% - 90% depending on age, hygiene, eating habits and geographical area. The risk of infection with *T. gondii* is higher in warm and humid climate. Rapid intracellular proliferation of *T. gondii* leads to damage of the reticuloendothelial system during the acute phase of infection (4).

Host defense mechanisms against *T. gondii* infection involve both cellular T-helper 1 (Th-1) and humoral T-helper 2 (Th-2) responses. Specific IgG antibodies can lyse extracellular trophozoites, but activation of T-cells and natural killer cells appear to be more important in preventing disease progression (5).

Infection with *T. gondii* leads to activation of T-helper cells (Th-1 and Th-2) which are involved in the synthesis and release of different cytokines, Th-1 produce interleukin-1 (IL-1), interferon-gamma (IFN- γ), and tumor necrosis factor alpha (TNF- α); while Th-2 produce interleukin-4 (IL-4),

interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-9 (IL-9) and interleukin-13 (IL-13) (6). In addition, nitric oxide has been found to play an important role in the immune response against growth of many protozoa including *T. gondii*, it is produced during the acute phase of infection leading to death of the intracellular organism (7).

Endothelial dysfunction is a systemic disorder of endothelium. The endothelium is responsible for keeping vascular tone and controlling oxidative stress by releasing mediators such as nitric oxide (NO), endothelin, and prostacyclin and regulating angiotensin-II activity. Reduction of vascular endothelium in response to appropriate stimuli is the main feature of endothelial dysfunction (8).

Endothelin 1 (ET-1), also known as preproendothelin-1 (PPET1), is a potent vasoconstrictor produced by vascular endothelial cells. Endothelin 1 is one of three isoforms of human endothelin. Pre-pro-endothelin is the precursor of the peptide ET-1. Endothelial cells convert pre-pro-endothelin to pro-endothelin and subsequently to mature endothelin, which the cells release (9). The ET-1 serum level reflects endothelial dysfunction in the different chronic infections (10).

Oxidative stress, which causes the overproduction of free radicals and/or reduction of endogenous antioxidant capacity leads to severe endothelial dysfunction. Pathogenesis of *T. gondii* is linked with induction of oxidative stress (11).

Lipid peroxidation and oxidative stress have been regarded as the main factors responsible for the generation of free radicals which leads to platelet and leukocyte adhesion to the vascular endothelium causing vasoconstriction and augmentation of peripheral vascular resistance. Malondialdehyde (MDA), is a biomarker of lipid peroxidation and oxidative stress, and increases in chronic acquired toxoplasmosis (12, 13).

2. Objectives

The aim of the present study was to evaluate the endothelial function in patients with acquired toxoplasmosis.

3. Methods

This case-control study involved 31 patients (27 female + 4 male) with toxoplasmosis aged 19 - 47 years matched with 20 healthy subjects (14 female + 6 male). This study was done in the Department of Clinical Pharmacology and Therapeutics in Cooperation with the Department of Medical Microbiology in the College of Medicine, Al-Mustansiriya University, Iraq-Baghdad, 2019. This clinical

study was completed and permitted by the explicit controlled ethical committee in respect to the Declaration of Helsinki. Full medical history, clinical examination and stereological tests were done for all patients and healthy controls, to confirm the acquired infection in the patients, and to exclude healthy controls with asymptomatic infections.

Exclusion criteria included; psychological diseases, neurological diseases, hypothyroidism, end-stage kidney disease, hepatic dysfunction, connective tissue disorders, malignant disorders and immunodeficiency.

3.1. Assessment of Biochemical Variables

Five milliliter of venous blood was obtained from the antecubital area of each patient and healthy subject, the blood was centrifuged at 3000/rpm and stored at -20°C for further analysis.

3.2. Serological Tests

Anti-*T. gondii* antibody (IgG, IgM, IgA) was determined by direct antigen-antibody reaction (CTK biotech. Inc., USA). This test is a panel rapid test and depends on lateral flow chromatographic immunoassay.

3.3. Assessment the Biomarkers of Endothelial Dysfunction

Interleukin-6 (IL-6) serum level was measured by ELISA kit method (Human IL-6 Kit, high sensitive, ab46042, Abcam, USA) which expressed as pg/mL with a sensitivity range (1.56 - 50 pg/mL). The endothelin-1 serum level was measured by ELISA kit method (endothelin-1 ELISA Kit, ab133030, Abcam, USA) which is expressed as pg/mL with sensitivity range (0.78 - 100 pg/mL). Human malondialdehyde (MDA) was measured by ELISA kit method (Colorimetric/Fluorometric, ab118970, Abcam, USA).

3.4. Statistical Analysis

The data is presented as mean \pm SD and unpaired student *t*-test was used to determine the differences. Correlation coefficient was used to estimate the significance of correlation among different variables. Data analysis was done by using SPSS (IBM SPSS Statistics for Windows version 20.0, 2014 Armonk, NY, IBM, Corp, USA). The level of significance was considered when $P < 0.05$.

4. Results

In the present study there were insignificant differences regarding age, gender, marital status and history of contact with animals ($P > 0.05$). On the other hand,

there was significant difference concerning history of recurrent abortion, which was high in the infected patients compared with control ($P = 0.0001$). In addition, smoking history was low in the infected patients compared with control ($P = 0.02$). In this study, 100% of infected patients with *T. gondii* illustrated positive for IgM and 90.32% for IgG. Likewise, 15% of control subjects showed test for IgG. Furthermore, 25.80% and 74.19% of infected patients with *T. gondii* were treated with spiramycin and clindamycin respectively. Other characteristics of the present study are presented in [Table 1](#).

Table 1. Demographic characteristics of the present study^a

The Characteristics	Control (N = 20)	Patients (N = 31)	P
Age, y	31.78 ± 9.28	33.67 ± 8.41	0.45
Gender, M:F ratio	6:14	4:27	
Male	4 (20)	4 (12.90)	0.50
Female	14 (70)	27 (87.09)	0.13
Marital status			
Married	11 (78.57)	21 (77.78)	0.94
Unmarried	3 (21.43)	6 (22.21)	0.93
History of recurrent abortion	1 (7.14)	18 (66.67)	0.0001 ^b
History of contact with animals	13 (65.00)	25 (80.64)	0.21
Smoking	7 (35.00)	3 (9.68)	0.02 ^c
Associated diseases			
Hypertension		9 (29.03)	
Asthma		3 (9.67)	
Dyslipidemia		8 (25.80)	
Peptic ulcer		3 (9.67)	
Current therapy			
Aspirin	6 (30.00)	14 (45.16)	
Theophylline		3 (9.67)	0.28
Statins		8 (25.80)	
Lanzoprazole		3 (9.67)	
IgM positive		31 (100)	
IgG positive	3 (15.00)	28 (90.32)	0.0001 ^b
Ant-toxoplasmosis agents			
Spiramycin		8 (25.80)	
Clindamycin		23 (74.19)	

^aValues are expressed as mean ± SD or No. (%).

^b $P < 0.01$.

^c $P < 0.05$.

Regarding immunological and immunoglobulin

changes in patients with acute toxoplasmosis, IgM, IgG and IgA levels were high in the infected patients compared with control ($P < 0.01$). Furthermore, IL-6 serum level was high in the infected patients (3.22 ± 1.61 pg/mL) compared with control (1.88 ± 0.51 pg/mL) ($P < 0.01$). In addition, biomarkers of endothelial dysfunction were augmented in patients with acute toxoplasmosis, ET-1 level was high in acute toxoplasmosis (7.29 ± 4.59 pg/mL) compared with control (3.11 ± 1.69 pg/mL) ($P < 0.01$). As well, MDA serum level was high (9.34 ± 4.17 nmol/mL) compared with control (2.87 ± 1.13 nmol/mL), ($P < 0.01$), [Table 2](#).

In acute toxoplasmosis, IgM serum level was significantly correlated with IgG ($r = 0.55$, $P = 0.001$), IgA ($r = 0.57$, $P = 0.0008$), IL-6 ($r = 0.45$, $P = 0.01$), ET-1 ($r = 0.51$, $P = 0.003$) and MDA ($r = 0.85$, $P = 0.0001$), [Table 3](#).

5. Discussion

For clinical purposes, toxoplasmosis can be divided for convenience into five infection categories, including: acquired by immune-competent patients, acquired during pregnancy, acquired congenitally; and acquired by or reactivated in immunodeficient patients, and including ocular infections. In any category, the clinical presentations are not specific for toxoplasmosis, and a wide differential diagnosis must be considered. Furthermore, methods of diagnosis and their interpretations may differ for each clinical category ([14](#)).

Toxoplasmosis in immune-competent patients is frequently asymptomatic or presented as flu-like symptoms, but in immune-compromised patients *T. gondii* leads to a serious fatal infection with multi-organ involvement ([15](#)). In the present study all of the recruited patients were immune-competent that explains the mild clinical presentation of acquired toxoplasmosis in the recruited patients.

Diagnosis of acute acquired infection of *T. gondii* depends on detection of specific antibodies against antigens of *T. gondii*. Serology for detection of IgM and IgG should be done in recognition of toxoplasmosis while IgA test gives supplementary evidence concerning reactivation or acute infection. An increase of IgM, IgG and IgA levels occurs in an acute infection while high IgG and IgA with negative tests for IgM occurs in reactivation but not in acute infection ([16](#)). These findings explain the high levels of IgG, IgM and IgA in the present study since all of the recruited patients were with acute infection of *T. gondii*. During acute toxoplasmosis, IgM appears early in plasma and rapidly declines, but IgG may persist for months to years following acute infection, therefore; a negative test for IgG excludes acute toxoplasmosis. Consequently, diagnoses of acute infection based on a fourfold increase in IgG with or without

Table 2. Changes in the Immunoglobulin Levels, Pro-Inflammatory and Oxidative Stress Biomarkers in Patients with Acute Toxoplasmosis^a

Variables	Control (N = 20)	Patients (N = 31)	95% CI	P
IgM, g/L	1.2 ± 0.8	3.6 ± 2.99	1.0213 - 3.778	0.001 ^a
IgG, g/L	4.31 ± 2.95	22.96 ± 9.57	10.1073 - 19.192	0.0001 ^a
IgA, g/L	1.99 ± 1.34	4.72 ± 2.54	1.4877 - 3.9723	0.0001 ^a
IL-6, pg/mL	1.88 ± 0.51	3.22 ± 1.61	0.5912 - 2.088	0.0007 ^a
ET-1, pg/mL	3.11 ± 1.69	7.29 ± 4.59	2.0230 - 6.3370	0.0003 ^a
MDA, nmol/mL	2.87 ± 1.13	9.34 ± 4.17	4.5462 - 8.3938	0.00001 ^a

Abbreviations: ET-1, endothelin; IL-6, interleukin-6; MDA, malondialdehyde.

^aValues are expressed as mean ± SD.

^aP < 0.01.

Table 3. Correlations of IgM Levels with Immunoglobulin Levels, Pro-Inflammatory and Oxidative Stress Biomarkers in Patients with Acute Toxoplasmosis^a

Variables	Control (N = 20)		Patients (N = 31)	
	r	P	r	P
IgG, g/L	0.26	0.26	0.55	0.001 ^b
IgA, g/L	0.22	0.35	0.57	0.0008 ^b
IL-6, pg/mL	0.19	0.42	0.45	0.01 ^c
ET-1, pg/mL	0.28	0.23	0.51	0.003 ^b
MDA, nmol/mL	0.20	0.39	0.85	0.0001 ^b

Abbreviations: ET-1, endothelin; IL-6, interleukin-6; MDA, malondialdehyde.

^ar, correlation; P, significant level.

^bP < 0.01.

^cP < 0.05.

positive test for IgM as both IgG and IgM are highly sensitive and specific (17). In the present study there was a significant fivefold increase in IgG level that confirms the acute toxoplasmosis, while the IgA serum level was increased significantly compared with healthy control subjects. These findings are in agreement with Olariu et al. (18), a study that illustrated high IgA serum level is correlated with accuracy and sensitivity of the serological panel for diagnosis of acquired acute toxoplasmosis.

The results of the present study illustrated that MDA serum level was high in patients with acute toxoplasmosis compared with controls due to induction of oxidative stress and lipid peroxidation. Dincel and Atmaca's study (19) confirmed that high level of MDA is associated with acute toxoplasmosis due to induction of oxidative stress and reduction of endogenous anti-oxidant capacity.

Indeed, the present study demonstrated a significant increase in the biomarkers of endothelial dysfunction, as both endothelin-1 and IL-6 were elevated in patients with acute toxoplasmosis compared with healthy control subjects. These findings are in concurrence with Knight et al.' study (20), which illustrated significant endothelial damage caused *T. gondii* during acute infection.

It has been reported, that *T. gondii* induces endothe-

lial inflammatory changes due to activation of pro-inflammatory cytokines. As well, chronic toxoplasmosis leads to cholesterol esterification, endothelial foam cell formation and development of endothelial dysfunction. Foam cells secrete IL-6 which causes leukocyte adhesion and provokes the expression of adhesion molecules on the endothelial cell (21).

Moreover, free *T. gondii* tachyzoites cross endothelial cells via intercellular adhesion molecule-1 (ICAM-1) therefore; in vitro inhibition of ICAM-1 prevents trans-endothelial migration of *T. gondii* tachyzoites. In addition, monocytes and dendritic cells are highly permissive for *T. gondii* tachyzoites due to different susceptibility for binding to parasitic tachyzoites. These changes stimulate monocyte adhesion to the endothelium causing significant endothelial dysfunction (22).

Therefore, endothelial cells respond to these inflammatory changes by secreting IL-6 which down-regulates and attenuates endothelial damage; thus; IL-6 is regarded as a biomarker of endothelial dysfunction (23). These findings confirm our results that described high IL-6 in acute toxoplasmosis.

On the other hand, MDA is a marker of lipid peroxidation and oxidized low density lipoprotein (ox-LDL) which

are increased during toxoplasmosis induced-oxidative stress. Acute oxidative stress leads to endothelial intracellular lysosomal membrane damage. Bahrami et al. (24), illustrated that *T. gondii* acquired cholesterol for their replication from the host LDL receptor pathway and also scavenged different lipids from the host cell.

Therefore, oxidative stress and induction of pro-inflammatory cytokines are interrelated in the induction of endothelial dysfunction in acute toxoplasmosis. Our findings revealed that levels of endothelin-1 and IL-6 were increased during acute toxoplasmosis. A recent animal model study by Estado et al. (25), showed that mice infected with *T. gondii* illustrated an exaggeration of leukocyte adhesion to the endothelial cells that caused endothelial dysfunction. Also, therapy with sulfadiazine improves endothelial dysfunction in acute toxoplasmosis through reduction of parasitic load and related endothelial inflammations (25).

Moreover, statins improve endothelial dysfunction in patients with toxoplasmosis due to the protective effect of statins. Besides, statins inhibit adhesion and proliferation of *T. gondii* (26, 27).

Moreover, toxoplasmosis was linked to the induction and progress of pregnancy induced-hypertension due to induction of oxidative stress and endothelial dysfunction. Therefore, long lasting spiramycin therapy during pregnancy reduces the risk of pregnancy induced-hypertension and pre-eclampsia (28).

5.1. Conclusions

Acute toxoplasmosis is associated with significant oxidative stress and pro-inflammatory changes which contribute in the development of endothelial dysfunction.

Footnotes

Authors' Contribution: All authors contributed equally in data collection, data acquisition and analysis, data interpretations, manuscript writing, and finally all authors approved the final version of the manuscript for publication.

Conflict of Interests: The authors declare there is no conflict of interest.

Ethical Approval: This study was approved in our local Ethics Committee with ethic code: MRT76 in 23/2/2019.

Funding/Support: There was no financial support for this study.

Informed Consent: Informed verbal consent was given from all participants and healthy controls for their involvement in this study. I confirm that the participants were given an opportunity to ask questions about the study, and

all the questions asked by the participants have been answered correctly and to the best of my ability. I confirm that the individual has not been coerced into giving consent, and the consent has been given freely and voluntarily.

References

- Dubey JP. *Toxoplasmosis of animals and humans*. United States: CRC Press; 2016. 19 p. eng. doi: [10.1201/9781420092370](https://doi.org/10.1201/9781420092370).
- Pomares C, Montoya JG. Laboratory diagnosis of congenital toxoplasmosis. *J Clin Microbiol*. 2016;**54**(10):2448–54. doi: [10.1128/JCM.00487-16](https://doi.org/10.1128/JCM.00487-16). [PubMed: [27147724](https://pubmed.ncbi.nlm.nih.gov/27147724/)]. [PubMed Central: [PMC5035424](https://pubmed.ncbi.nlm.nih.gov/PMC5035424/)].
- Montazeri M, Sharif M, Sarvi S, Mehrzadi S, Ahmadpour E, Daryani A. A systematic review of in vitro and in vivo activities of anti-Toxoplasma DRUGS AND COMPOUNDS (2006-2016). *Front Microbiol*. 2017; doi: [10.3389/fmicb.2017.00025](https://doi.org/10.3389/fmicb.2017.00025). [PubMed: [28163699](https://pubmed.ncbi.nlm.nih.gov/28163699/)]. [PubMed Central: [PMC5247447](https://pubmed.ncbi.nlm.nih.gov/PMC5247447/)].
- Matowicka-Karna J, Dymicka-Piekarska V, Kemon H. Does Toxoplasma gondii infection affect the levels of IgE and cytokines (IL-5, IL-6, IL-10, IL-12, and TNF-alpha)? *Clin Dev Immunol*. 2009;**2009**:374696. doi: [10.1155/2009/374696](https://doi.org/10.1155/2009/374696). [PubMed: [19478959](https://pubmed.ncbi.nlm.nih.gov/19478959/)]. [PubMed Central: [PMC2685994](https://pubmed.ncbi.nlm.nih.gov/PMC2685994/)].
- Kim JH, Lee J, Bae SJ, Kim Y, Park BJ, Choi JW, et al. NADPH oxidase 4 is required for the generation of macrophage migration inhibitory factor and host defense against Toxoplasma gondii infection. *Sci Rep*. 2017;**7**(1):6361. doi: [10.1038/s41598-017-06610-4](https://doi.org/10.1038/s41598-017-06610-4). [PubMed: [28743960](https://pubmed.ncbi.nlm.nih.gov/28743960/)]. [PubMed Central: [PMC5526938](https://pubmed.ncbi.nlm.nih.gov/PMC5526938/)].
- O'Brien CA, Batista SJ, Still KM, Harris TH. IL-10 and ICOS differentially regulate T cell responses in the brain during chronic Toxoplasma gondii infection. *J Immunol*. 2019;**202**(6):1755–66. doi: [10.4049/jimmunol.1801229](https://doi.org/10.4049/jimmunol.1801229). [PubMed: [30718297](https://pubmed.ncbi.nlm.nih.gov/30718297/)]. [PubMed Central: [PMC6401250](https://pubmed.ncbi.nlm.nih.gov/PMC6401250/)].
- Yan X, Ji Y, Liu X, Suo X. Nitric oxide stimulates early egress of Toxoplasma gondii tachyzoites from Human foreskin fibroblast cells. *Parasit Vectors*. 2015;**8**:420. doi: [10.1186/s13071-015-1037-5](https://doi.org/10.1186/s13071-015-1037-5). [PubMed: [26264067](https://pubmed.ncbi.nlm.nih.gov/26264067/)]. [PubMed Central: [PMC4534117](https://pubmed.ncbi.nlm.nih.gov/PMC4534117/)].
- Adesse D, Marcos AC, Siqueira M, Cascabulho CM, Waghabi MC, Barbosa HS, et al. Radial Glia cell infection by Toxoplasma gondii disrupts brain microvascular endothelial cell integrity. *bioRxiv*. 2018;**1**:378588. doi: [10.1101/378588](https://doi.org/10.1101/378588).
- Kadhim SS, Al-Windy SA, Al-Kuraishy HM, Al-Gareeb AI. Endothelin-1 is a surrogate biomarker link severe periodontitis and endothelial dysfunction in hypertensive patients: The potential nexus. *J Int Oral Health*. 2019;**11**(6):369.
- Feustel SM, Meissner M, Liesenfeld O. Toxoplasma gondii and the blood-brain barrier. *Virulence*. 2012;**3**(2):182–92. doi: [10.4161/viru.19004](https://doi.org/10.4161/viru.19004). [PubMed: [22460645](https://pubmed.ncbi.nlm.nih.gov/22460645/)]. [PubMed Central: [PMC3396697](https://pubmed.ncbi.nlm.nih.gov/PMC3396697/)].
- Parlog A, Schluter D, Dunay IR. Toxoplasma gondii-induced neuronal alterations. *Parasite Immunol*. 2015;**37**(3):159–70. doi: [10.1111/pim.12157](https://doi.org/10.1111/pim.12157). [PubMed: [25376390](https://pubmed.ncbi.nlm.nih.gov/25376390/)].
- Al-Kuraishy HM, Al-Gareeb AI, Al-Maiah TJ. Concept and connotation of oxidative stress in preeclampsia. *J Lab Physicians*. 2018;**10**(3):276–82. doi: [10.4103/JLP.JLP_26_18](https://doi.org/10.4103/JLP.JLP_26_18). [PubMed: [30078962](https://pubmed.ncbi.nlm.nih.gov/30078962/)]. [PubMed Central: [PMC6052821](https://pubmed.ncbi.nlm.nih.gov/PMC6052821/)].
- Karaman U, Celik T, Kiran TR, Colak C, Daldal NU. Malondialdehyde, glutathione, and nitric oxide levels in Toxoplasma gondii seropositive patients. *Korean J Parasitol*. 2008;**46**(4):293. doi: [10.3347/kjp.2008.46.4.293](https://doi.org/10.3347/kjp.2008.46.4.293). [PubMed: [19127340](https://pubmed.ncbi.nlm.nih.gov/19127340/)].
- Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. *J Infect Dis*. 2002;**185** Suppl 1:S73–82. doi: [10.1086/338827](https://doi.org/10.1086/338827). [PubMed: [11865443](https://pubmed.ncbi.nlm.nih.gov/11865443/)].

15. Wang ZD, Liu HH, Ma ZX, Ma HY, Li ZY, Yang ZB, et al. Toxoplasma gondii infection in immunocompromised patients: A systematic review and meta-analysis. *Front Microbiol.* 2017;**8**:389. doi: [10.3389/fmicb.2017.00389](https://doi.org/10.3389/fmicb.2017.00389). [PubMed: [28337191](https://pubmed.ncbi.nlm.nih.gov/28337191/)]. [PubMed Central: [PMC5343064](https://pubmed.ncbi.nlm.nih.gov/PMC5343064/)].
16. Pomares C, Zhang B, Arulkumar S, Gonfrier G, Marty P, Zhao S, et al. Validation of IgG, IgM multiplex plasmonic gold platform in French clinical cohorts for the serodiagnosis and follow-up of Toxoplasma gondii infection. *Diagn Microbiol Infect Dis.* 2017;**87**(3):213-8. doi: [10.1016/j.diagmicrobio.2016.09.001](https://doi.org/10.1016/j.diagmicrobio.2016.09.001). [PubMed: [28040304](https://pubmed.ncbi.nlm.nih.gov/28040304/)].
17. Calderaro A, Piccolo G, Peruzzi S, Gorrini C, Chezzi C, Dettori G. Evaluation of Toxoplasma gondii immunoglobulin G (IgG) and IgM assays incorporating the newVidia analyzer system. *Clin Vaccine Immunol.* 2008;**15**(7):1076-9. doi: [10.1128/CVI.00025-08](https://doi.org/10.1128/CVI.00025-08). [PubMed: [18480234](https://pubmed.ncbi.nlm.nih.gov/18480234/)]. [PubMed Central: [PMC2446631](https://pubmed.ncbi.nlm.nih.gov/PMC2446631/)].
18. Olariu TR, Blackburn BG, Press C, Talucod J, Remington JS, Montoya JG. Role of Toxoplasma IgA as part of a reference panel for the diagnosis of acute toxoplasmosis during pregnancy. *J Clin Microbiol.* 2019;**57**(2). doi: [10.1128/JCM.01357-18](https://doi.org/10.1128/JCM.01357-18). [PubMed: [30463899](https://pubmed.ncbi.nlm.nih.gov/30463899/)]. [PubMed Central: [PMC6355551](https://pubmed.ncbi.nlm.nih.gov/PMC6355551/)].
19. Dincel GC, Atmaca HT. Role of oxidative stress in the pathophysiology of Toxoplasma gondii infection. *Int J Immunopathol Pharmacol.* 2016;**29**(2):226-40. doi: [10.1177/0394632016638668](https://doi.org/10.1177/0394632016638668). [PubMed: [26966143](https://pubmed.ncbi.nlm.nih.gov/26966143/)]. [PubMed Central: [PMC5806720](https://pubmed.ncbi.nlm.nih.gov/PMC5806720/)].
20. Knight BC, Brunton CL, Modi NC, Wallace GR, Stanford MR. The effect of Toxoplasma gondii infection on expression of chemokines by rat retinal vascular endothelial cells. *J Neuroimmunol.* 2005;**160**(1-2):41-7. doi: [10.1016/j.jneuroim.2004.10.023](https://doi.org/10.1016/j.jneuroim.2004.10.023). [PubMed: [15710456](https://pubmed.ncbi.nlm.nih.gov/15710456/)].
21. Konradt C, Hunter CA. Pathogen interactions with endothelial cells and the induction of innate and adaptive immunity. *Eur J Immunol.* 2018;**48**(10):1607-20. doi: [10.1002/eji.201646789](https://doi.org/10.1002/eji.201646789). [PubMed: [30160302](https://pubmed.ncbi.nlm.nih.gov/30160302/)]. [PubMed Central: [PMC6172149](https://pubmed.ncbi.nlm.nih.gov/PMC6172149/)].
22. Furtado JM, Bharadwaj AS, Chipps TJ, Pan Y, Ashander LM, Smith JR. Toxoplasma gondii tachyzoites cross retinal endothelium assisted by intercellular adhesion molecule-1 in vitro. *Immunol Cell Biol.* 2012;**90**(9):912-5. doi: [10.1038/icb.2012.21](https://doi.org/10.1038/icb.2012.21). [PubMed: [22525368](https://pubmed.ncbi.nlm.nih.gov/22525368/)]. [PubMed Central: [PMC3475739](https://pubmed.ncbi.nlm.nih.gov/PMC3475739/)].
23. O'Carroll SJ, Kho DT, Wiltshire R, Nelson V, Rotimi O, Johnson R, et al. Pro-inflammatory TNFalpha and IL-1beta differentially regulate the inflammatory phenotype of brain microvascular endothelial cells. *J Neuroinflammation.* 2015;**12**:131. doi: [10.1186/s12974-015-0346-0](https://doi.org/10.1186/s12974-015-0346-0). [PubMed: [26152369](https://pubmed.ncbi.nlm.nih.gov/26152369/)]. [PubMed Central: [PMC4506411](https://pubmed.ncbi.nlm.nih.gov/PMC4506411/)].
24. Bahrami S, Shahriari A, Tavalla M, Azadmanesh S, Hamidinejat H. Blood Levels of Oxidant/Antioxidant Parameters in Rats Infected with Toxoplasma gondii. *Oxid Med Cell Longev.* 2016;**2016**:8045969. doi: [10.1155/2016/8045969](https://doi.org/10.1155/2016/8045969). [PubMed: [27746857](https://pubmed.ncbi.nlm.nih.gov/27746857/)]. [PubMed Central: [PMC5056297](https://pubmed.ncbi.nlm.nih.gov/PMC5056297/)].
25. Estato V, Stipursky J, Gomes F, Mergener TC, Frazao-Teixeira E, Allodi S, et al. The neurotropic parasite Toxoplasma gondii induces sustained neuroinflammation with microvascular dysfunction in infected mice. *Am J Pathol.* 2018;**188**(11):2674-87. doi: [10.1016/j.ajpath.2018.07.007](https://doi.org/10.1016/j.ajpath.2018.07.007). [PubMed: [30121257](https://pubmed.ncbi.nlm.nih.gov/30121257/)].
26. Al-Kuraishy HM, Al-Gareeb AI. Acylation-stimulating protein is a surrogate biomarker for acute myocardial infarction: Role of statins. *J Lab Physicians.* 2017;**9**(3):163-9. doi: [10.4103/0974-2727.208263](https://doi.org/10.4103/0974-2727.208263). [PubMed: [28706385](https://pubmed.ncbi.nlm.nih.gov/28706385/)]. [PubMed Central: [PMC5496293](https://pubmed.ncbi.nlm.nih.gov/PMC5496293/)].
27. Sanfelice RA, da Silva SS, Bosqui LR, Miranda-Sapla MM, Barbosa BF, Silva RJ, et al. Pravastatin and simvastatin inhibit the adhesion, replication and proliferation of Toxoplasma gondii (RH strain) in HeLa cells. *Acta Trop.* 2017;**167**:208-15. doi: [10.1016/j.actatropica.2016.12.006](https://doi.org/10.1016/j.actatropica.2016.12.006). [PubMed: [28012901](https://pubmed.ncbi.nlm.nih.gov/28012901/)].
28. Todros T, Verdiglione P, Ogge G, Paladini D, Vergani P, Cardaropoli S. Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for toxoplasma infection. *Br J Clin Pharmacol.* 2006;**61**(3):336-40. doi: [10.1111/j.1365-2125.2005.02572.x](https://doi.org/10.1111/j.1365-2125.2005.02572.x). [PubMed: [16487228](https://pubmed.ncbi.nlm.nih.gov/16487228/)]. [PubMed Central: [PMC1885027](https://pubmed.ncbi.nlm.nih.gov/PMC1885027/)].